Lupin announces plans to build a new state-of-the-art pharmaceutical manufacturing plant in Coral Springs, Florida, with a projected investment of $250 million. The facility will produce over 25 critical respiratory medicines, including albuterol inhalers. This project aims to strengthen domestic manufacturing, enhance supply chain security, and create over 200 new skilled jobs by 2030.
New Manufacturing Facility
Lupin is investing in a new state-of-the-art pharmaceutical manufacturing plant in Coral Springs, Florida, reinforcing its commitment to the health and safety of Florida families and the nation. The company plans to invest $250 million over five years, including research and development and infrastructure expenditures. The announcement was made on October 8, 2025.
Production Capacity
The new facility will have the capacity to manufacture more than 25 critical respiratory medicines, including life-saving albuterol inhalers. This production will support both domestic and overseas needs, enhancing the availability of vital medications. This initiative strengthens Lupin’s position as a key player in the respiratory medicine sector.
Economic Impact and Job Creation
The project is expected to generate over 200 new long-term, skilled jobs by 2030 in Broward County, Florida. The expansion of Lupin’s presence in Coral Springs is a core element of its growth strategy and builds on its existing operations in Florida. The company already has its headquarters and Advanced Inhalation Research Center located in the state.
Strategic Partnerships and Incentives
Lupin is partnering with various Florida entities, including FloridaCommerce and the City of Coral Springs. The company will receive tax credits and incentives from the state of Florida in recognition of its investment and job creation plans. These partnerships are integral to the success of the new manufacturing plant.
Source: BSE
